4. In accordance with the provisions of Section 35DD of the Act, where a company incurs any expenditure incurred wholly and

exclusively for the purposes of amalgamation or demerger of an undertaking, the company shall be allowed a deduction of an
amount equal to one-fifth of such expenditure for each of the five successive years beginning with the year in which
amalgamation or demerger takes place.

We have been informed by the Company that pursuant to the approval of the scheme of amalgamation between the Company
and Ritemed Pharma Retail Private Limited (‘(RMPL’) by National Company Law Tribunal at Hyderabad on 14 August 2018,
RMPL has been amalgamated with the Company with effect from 01 April 2016. In this regard, the Company will be eligible
for a deduction of one-fifth expenses related to aforesaid merger which was disallowed in earlier years from the Financial Year
2018-19 to 2022-23.

NOTES:

1. The above is as per the current tax laws, as amended by the Finance Act, 2021.

2. The above Statement of possible special tax benefits sets out the provisions of Tax Laws in a summary manner only and is
not a complete analysis or listing of all the existing and potential tax consequences of the purchase, ownership and disposal
of equity shares of the Company.

3. The possible special tax benefits are subject to conditions and eligibility criteria which need to be examined for tax
implications.

4. This Statement does not discuss any tax consequences in any country outside India of an investment in the equity shares
of the Company. The Shareholders / investors in any country outside India are advised to consult their own professional
advisors regarding possible income tax consequences that apply to them under the laws of such jurisdiction.

5. The tax benefits discussed in the Statement are not exhaustive and are only intended to provide general information to
the investors and hence, is neither designed nor intended to be a substitute for professional tax advice. In view of the
individual nature of the tax consequences and the changing tax laws, each investor is advised to consult his or her own
tax consultant with respect to the specific tax implications arising out of their participation in the issue

6. In respect of non-residents, the tax rates and the consequent taxation mentioned above shall be further subject to any

benefits available under the applicable double taxation avoidance agreement, if any, between India and the country in
which the non-resident has fiscal domicile.

For MedPlus Health Services Limited (formerly known as MedPlus Health Services Private Limited)

G. Madhukar Reddy Hemanth Kundavaram
Managing Director Chief Financial Officer
Place: Hyderabad Place: Hyderabad

Date: December 3, 2021 Date: December 3, 2021

123
